<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004221</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-9903</org_study_id>
    <secondary_id>NCI-2012-02312</secondary_id>
    <secondary_id>CDR0000067462</secondary_id>
    <secondary_id>GOG-9903</secondary_id>
    <secondary_id>GOG-9903</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00004221</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer</brief_title>
  <official_title>A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Optimally Debulked Stage III Ovarian and Primary Peritoneal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Group</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of combination chemotherapy and peripheral stem
      cell transplantation in treating patients who have undergone surgery for stage III ovarian
      cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. Determine the safety and feasibility of multiple courses of high dose carboplatin,
      paclitaxel, and topotecan as initial chemotherapy combined with autologous peripheral blood
      stem cell transplantation in patients with optimally debulked stage III ovarian or primary
      peritoneal carcinoma.

      II. Determine the pathological complete response rate, disease free survival, and overall
      survival in patients treated with this regimen.

      OUTLINE: This is a multicenter study.

      Mobilization and harvest: Within 8 weeks of surgical debulking, patients receive
      cyclophosphamide IV over 1 hour, followed 4 hours later by paclitaxel IV over 24 hours.
      Patients receive filgrastim (G-CSF) subcutaneously (SQ) daily beginning 24 hours after
      completion of paclitaxel infusion and continuing until blood counts recover and autologous
      peripheral blood stem cells (PBSC) are harvested and selected for CD34+ cells.

      High dose chemotherapy and transplantation (3 weeks after PBSC harvest): Patients receive
      paclitaxel IV over 24 hours beginning on day 1, immediately followed by carboplatin IV over 2
      hours, immediately followed by topotecan IV over 24 hours. Patients receive G-CSF
      sub-cutaneously (SQ) daily beginning 24 hours after completion of topotecan infusion and
      continuing until blood counts have recovered for 2 days. One quarter of the PBSC are
      reinfused beginning 2 days after completion of topotecan infusion. Treatment repeats every 4
      weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients
      with radiographic and biochemical complete response undergo laparoscopy as second look
      surgery within 8 weeks of the last course of chemotherapy. If no evidence of disease is found
      during laparoscopy, then exploratory laparotomy must also be performed.

      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
      annually thereafter or at time of recurrence until death.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>November 1999</start_date>
  <primary_completion_date type="Actual">February 6, 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response defined as complete disappearance of all measurable and evaluable tumor documented at second-look surgery</measure>
    <time_frame>Up to 11 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Indication of excessive toxicity defined as hospitalization &gt; 14 days per course, delay of day 1 therapy &gt; 14 days, or grade 3 (irreversible) or grade 4 vital organ toxicity (non-hematologic)</measure>
    <time_frame>Up to 11 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 11 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 11 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Malignant Ovarian Mixed Epithelial Tumor</condition>
  <condition>Ovarian Clear Cell Cystadenocarcinoma</condition>
  <condition>Ovarian Endometrioid Adenocarcinoma</condition>
  <condition>Ovarian Mucinous Cystadenocarcinoma</condition>
  <condition>Ovarian Serous Cystadenocarcinoma</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <condition>Stage III Ovarian Cancer</condition>
  <condition>Undifferentiated Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (Combination chemotherapy, PBSC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Combination chemotherapy, PBSC)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Combination chemotherapy, PBSC)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SQ</description>
    <arm_group_label>Treatment (Combination chemotherapy, PBSC)</arm_group_label>
    <other_name>Filgrastim XM02</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tbo-filgrastim</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Combination chemotherapy, PBSC)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous peripheral blood stem cell transplantation</description>
    <arm_group_label>Treatment (Combination chemotherapy, PBSC)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Combination chemotherapy, PBSC)</arm_group_label>
    <other_name>Hycamptamine</other_name>
    <other_name>Hycamtin</other_name>
    <other_name>SKF S-104864-A</other_name>
    <other_name>Topotecan HCl</other_name>
    <other_name>topotecan hydrochloride (oral)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven optimally debulked stage III ovarian or primary peritoneal
             carcinoma

               -  Any of the following subtypes:

                    -  Serous adenocarcinoma

                    -  Mucinous adenocarcinoma

                    -  Clear cell carcinoma

                    -  Transitional cell carcinoma

                    -  Endometrioid adenocarcinoma

                    -  Undifferentiated adenocarcinoma

                    -  Mixed epithelial adenocarcinoma

                    -  Adenocarcinoma, not otherwise specified

          -  No ovarian carcinoma of low malignant potential (borderline)

          -  Concurrent superficial endometrial or cervical carcinoma allowed if ovarian carcinoma
             more life threatening or limiting

          -  Must have undergone appropriate primary surgical staging and debulking for ovarian
             carcinoma and have less than 1 cm of residual disease

               -  No more than 8 weeks since prior surgical debulking

          -  Must have Hickman catheter in place or be eligible for placement

          -  No CNS involvement

          -  Performance status - GOG 0 or 1

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin no greater than 1.5 mg/dL

          -  SGOT or SGPT no greater than 2 times upper limit of normal

          -  No active hepatitis

          -  Creatinine no greater than 1.5 mg/dL

          -  Creatinine clearance at least 60 mL/min

          -  No renal failure

          -  Curatively treated ureteral obstruction allowed if above creatinine measurements met

          -  No congestive heart failure

          -  No myocardial infarction within the past 6 months

          -  No significant arrhythmias requiring medication

          -  No poorly controlled systolic or diastolic hypertension (diastolic blood pressure
             consistently greater than 100 mm Hg)

          -  No significant nonneoplastic pulmonary disease

          -  No other malignancy within the past 5 years except basal cell or squamous cell skin
             cancer or carcinoma in situ of the cervix

          -  HIV negative

          -  No other severe medical or psychiatric illness including, but not limited to the
             following:

               -  Acute infection

               -  Active peptic ulcer disease

               -  Uncontrolled diabetes mellitus

               -  Prior hospitalization for psychiatric illness, including severe depression or
                  psychosis

               -  Concurrent alcohol or drug abuse

          -  No prior chemotherapy for this malignancy

          -  No radiotherapy to greater than 25% of bone marrow

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell Schilder</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2000</study_first_submitted>
  <study_first_submitted_qc>August 22, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2003</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Cystadenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Cystadenocarcinoma, Mucinous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

